Rallybio Corp

Rallybio is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. The company's lead program is RLYB116, a complement component 5 ("C5") inhibitor designed to treat diseases caused by complement dysregulation. Additionally, Rallybio has RLYB332, a long-acting matriptase-2 ("MTP-2") antibody, which is in preclinical development for treating diseases of iron overload. On March 1, 2026, Rallybio entered into a Merger Agreement with Candid, a clinical-stage biotechnology company specializing in T-cell engager ("TCE") therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc. As part of this agreement, Merger Sub will merge into Candid, with Candid becoming a wholly-owned subsidiary of Rallybio. This Merger is intended to be a tax-free reorganization for U.S. federal income tax purposes. Concurrently, investors committed approximately $505.5 million in a Concurrent Financing to purchase Candid common stock, which will convert into Rallybio Common Stock upon the Merger.